Diseases of the brain affect more than 200 million people, manifesting at all ages and stages of life, and many of us know someone with a serious neurological disorder.4 At Voyager, we are working to unlock the enormous promise gene therapy has for treating these and other serious diseases.
“It’s personal to me because we are defined by our experiences. It is a tragedy that someone can be robbed of their memories and lose their identity built through a lifetime.”
Voyager’s mission is to develop and deliver life-changing gene therapies to people around the world. This begins with a commitment to excellence in research and development and world-class expertise in AAV vector engineering and neurobiology, and it extends to our engagement with academic and industry collaborators, healthcare providers, patients, caregivers, and advocates. We are committed to unlocking the full potential of AAV gene therapy to reshape the treatment landscape for neurological disorders and other serious diseases.
With a deep roster of experienced biopharmaceutical leaders and specialized expertise in gene therapy, the Voyager team is working relentlessly to develop new capsids that will enable safe and effective delivery of genetic payloads that could change the trajectory of disease and life as we know it for millions of people.